Trump Advisor Claims Internal Resistance Delays Cannabis Rescheduling
Senior administration official suggests federal agencies or departments are obstructing marijuana policy reform despite campaign promises.
A senior Trump administration advisor indicates internal federal resistance is preventing progress on cannabis rescheduling, marking a potential setback for the multi-billion dollar industry that anticipated swift regulatory reform. The comments suggest bureaucratic friction within federal agencies may be undermining the administration's stated cannabis policy objectives, creating uncertainty for operators and investors who factored rescheduling timelines into their strategic planning.
The alleged obstruction comes as cannabis companies face mounting pressure from high tax burdens under Section 280E, which prevents normal business deductions for federally illegal substances. Rescheduling cannabis from Schedule I to Schedule III would eliminate these tax penalties, potentially adding hundreds of millions in cash flow across major operators. Multi-state operators like Curaleaf, Green Thumb Industries, and Cresco Labs have built expansion strategies around anticipated federal tax relief that now faces unclear timelines.
Federal rescheduling represents the industry's most significant regulatory catalyst, with analysts estimating tax savings could boost sector-wide EBITDA margins by 15-20 percentage points. The delay compounds existing headwinds including state-level oversupply, margin compression, and limited interstate commerce that have pressured cannabis equity valuations throughout 2025. Major operators trading at steep discounts to traditional consumer goods companies need federal reform to unlock institutional investment and traditional banking services.
The administration's internal conflicts highlight the complex federal bureaucracy surrounding cannabis policy, where multiple agencies including DEA, FDA, and Treasury must coordinate implementation. Previous rescheduling efforts under the Biden administration faced similar inter-agency delays, suggesting structural resistance within federal departments regardless of executive branch priorities. This pattern indicates cannabis companies may need contingency strategies that don't rely on federal reform timelines.
Investors now face extended uncertainty around the industry's primary regulatory catalyst, potentially delaying the sector's transition from state-licensed operators to national consumer brands. Without clear federal progress, cannabis companies must continue navigating fragmented state markets while competing against illicit operators who avoid regulatory compliance costs entirely.